article thumbnail

A step closer to ‘clinical trial in a dish’ for Alzheimer’s  

Drug Discovery World

has paved the way for the use of cell-based assays to investigate drug safety and efficacy, including this innovative ‘clinical trial in a dish’ approach. Chris Ward, CSO and Co-founder, StrataStem, added: “We are delighted to be entering this collaboration with the team at Axol.

article thumbnail

Multi-target collaboration to advance cachexia therapeutics

Drug Discovery World

This has the potential to deliver a generation of future therapeutics with high tissue specificity, low toxicity, and ultimately, safer and more effective medicines.” The agreement covers activities ranging from hit ID to development of cell-based assays, with an option for Endevica to further develop the peptide hits resulting from the screening (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IRBM and Merck extend peptide therapeutics collaboration

Drug Discovery World

The post IRBM and Merck extend peptide therapeutics collaboration appeared first on Drug Discovery World (DDW).

article thumbnail

A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO

Covalent Modifiers

Herein, we used a targeted covalent inhibition strategy and identified a covalent inhibitor, TD19, which selectively inhibits ALKBH5 compared with FTO demethylase in protein-based and tumor cell-based assays. TD19 irreversibly modifies the residues C100 and C267, preventing ALKBH5 from binding to m6A-containing RNA.

RNA 75
article thumbnail

Atherosclerotic vascular disease | BMG LABTECH

BMG Labtech

In this blog, we highlight some of the solutions available for researchers to tackle atherosclerotic vascular disease: from fundamental research rooted in ischemia-reperfusion studies and cell-based assays to drug discovery efforts and the early detection of drug-related side effects. What is atherosclerotic vascular disease?

Disease 52
article thumbnail

Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri

Alta Sciences

All three laboratories across North America are uniformly designed and managed. Whether as a standalone bioanalytical service or as part of an integrated program, Altasciences provides top-quality data for TK, PK, and PD determinations to support preclinical and clinical studies.

article thumbnail

Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23 [Drug Discovery and Translational Medicine]

ASPET

Mirikizumab effectively inhibits the interaction of IL-23 with its receptor, and potently blocks IL-23-induced IL-17 production in cell-based assays while preserving the function of IL-12. In both local and systemic in vivo mouse models, mirikizumab blocked IL-23-induced keratin mRNA or IL-17 production, respectively.